<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885272</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0261</org_study_id>
    <secondary_id>NCI-2016-01971</secondary_id>
    <secondary_id>2016-0261</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02885272</nct_id>
  </id_info>
  <brief_title>FDG PET Imaging in Diagnosing Patients With Glioblastoma</brief_title>
  <official_title>Dual Time Point FDG PET Imaging Optimization for the Evaluation of Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies the how well fluorodeoxyglucose F-18 (FDG) positron emission
      tomography (PET) imaging works in diagnosing patients with confirmed or suspected
      glioblastoma. Diagnostic procedures, such as FDG PET, may help find and diagnose
      glioblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the optimal FDG positron emission tomography (PET) imaging time post radiotracer
      administration that maximizes separation of activity between lesion and non-lesional
      parenchyma (measured as lesion/background [L/B] ratio) in patients with glioblastoma.

      SECONDARY OBJECTIVES:

      I. To identify genotypic factors in FDG tumor metabolism derived from metrics such as maximum
      standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion glycolysis
      (TLG), mean tumor volume (MTV) and L/B ratio.

      EXPLORATORY OBJECTIVES:

      I. To identify patterns of metabolism derived from metrics such as SUVmax, SUVmean, TLG, MTV,
      L/B ratio and magnetic resonance imaging metrics such as regional perfusion abnormalities,
      apparent diffusion coefficient values, fractional diffusivity measures and magnetic resonance
      spectroscopic finding.

      OUTLINE:

      Patients receive fluorodeoxyglucose F-18 intravenously (IV) over 1 minute and then undergo
      PET/computed tomography (CT) scans over 30 minutes at 1 hour, 4-5 hours, and 7-8 hours after
      injection. Patients also undergo a standard of care magnetic resonance imaging (MRI) scan
      over 45 minutes if not already completed as part of standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2016</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in length-beam ratio</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be tested via paired t-test after appropriate transformation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative parametric maps based on biophysical principles or pharmacokinetic modeling</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be derived from magnetic resonance advanced brain tumor imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnetic resonance images of relative blood volume, blood flow, apparent diffusion coefficient and forward volumetric transfer constant</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be used to derive quantitative parametric maps based on biophysical principles or pharmacokinetic modeling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorodeoxyglucose F-18 uptake patterns</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be correlated with magnetic resonance images.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genotypic factors</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed via two-sample t-tests, for all genes of interest with at least 20% of mutation prevalence.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Brain Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fluorodeoxyglucose F-18 IV over 1 minute and then undergo PET/CT scans over 30 minutes at 1 hour, 4-5 hours, and 7-8 hours after injection. Patients also undergo a standard of care MRI scan over 45 minutes if not already completed as part of standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT scans</description>
    <arm_group_label>Diagnostic (PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (PET/CT)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo standard of care MRI</description>
    <arm_group_label>Diagnostic (PET/CT)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT scans</description>
    <arm_group_label>Diagnostic (PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt; 19 years of age) patients with biopsy proven (as opposed to being status post
             definitive surgical therapy) or highly suspected glioblastoma of the brain

          -  Cases without prior biopsy will be chosen based upon consensus of a MD Anderson
             faculty neuroradiologist and neurosurgeon for high probability of representing a
             glioblastoma

          -  T1 post contrast lesion size greater than or equal to 10 mm

        Exclusion Criteria:

          -  Children

          -  Definitive/gross total lesion resection

          -  Prior brain cancer

          -  Prior whole brain radiation

          -  Known history of cerebrovascular disease, dementia or prior non-mild traumatic brain
             injury

          -  Known allergy to FDG or gadolinium based contrast agents

          -  Pregnant women are excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason M Johnson</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Johnson, MD</last_name>
    <phone>713-792-8443</phone>
    <email>jjohnson12@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason M. Johnson</last_name>
      <phone>713-792-8443</phone>
    </contact>
    <investigator>
      <last_name>Jason M. Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

